sorry, we can't preview this file
12967_2021_3134_MOESM1_ESM.pptx (558.81 kB)
Additional file 1 of Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
presentation
posted on 2021-12-02, 05:34 authored by Rosaria De Filippi, Fortunato Morabito, Armando Santoro, Giovanni Tripepi, Francesco D’Alò, Luigi Rigacci, Francesca Ricci, Emanuela Morelli, Pier Luigi Zinzani, Antonio PintoAdditional file 1: Fig. S1. Study design, included and excluded patients. Fig. S2. Relationship between Body Mass Index (BMI) categories and potentially unfavorable disease-related baseline features. Fig. S3. Relationship between Body Mass Index (BMI) categories and types and number of previous therapies. Fig. S4. Forest plot of Cox univariate analysis for progression-free survival according to several variables. ASCT, autologous stem cell transplant, Allo-SCT, allogeneic stem cell transplant transplant.
